Moleculin Biotech, Inc. will present at the Annual Acute Leukemia Meeting in Madrid, Spain on October 30th. Dr. Paul Waymack will discuss the MIRACLE trial, a Phase 2B/3 study of Annamycin for refractory AML. Annamycin has Fast Track Status and Orphan Drug Designation for AML treatment. The Company is also developing WP1066 for brain tumors and other cancers. Moleculin aims to advance therapies for challenging tumors and viruses, with a focus on Annamycin for AML and STS lung metastases. For more information, visit the meeting website or Moleculin’s website. Contact JTC Team, LLC for investor inquiries.

Read more at GlobeNewswire: Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid